Pancreatic Cancer Research

ResearcherWashington University in St. LouisNo recent work listed

Hui Chin Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5838-5922; OpenAlex author ID A5048088729. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

  1. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1039226↗
  2. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Graham D. Hogg · 2 shared papers, 2021–2022 · strength 0.26
  2. William G. Hawkins · 2 shared papers, 2021–2022 · strength 0.26
  3. Chong Zuo · 2 shared papers, 2021–2022 · strength 0.26
  4. William E. Gillanders · 2 shared papers, 2021–2022 · strength 0.26
  5. David G DeNardo · 2 shared papers, 2021–2022 · strength 0.26
  6. Katharine E. Caldwell · 1 shared paper, 2021 · strength 0.11
  7. C. Alston James · 1 shared paper, 2021 · strength 0.11
  8. Ryan C Fields · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.